See termination reason in detailed description

This trial is conducted in the United States of America (USA). This trial will compare the changes in HbA1c after 26 weeks of inhaled insulin or rosiglitazone treatment, both in combination with metformin and glimepiride.

The decision to discontinue the development of AERx® is not due to any safety concerns. An analysis concluded that fast-acting inhaled insulin in the form it is known today, is unlikely to offer significant clinical or convenience benefits over injections of modern insulin with pen devices.

Inclusion Criteria:

• Type 2 diabetes
• Currently treated with antidiabetes drugs (including Exenatide) for at least 2 months
• HbA1c between 7.5 and 11.0% (both inclusive) on antidiabetes combination therapy
• BMI less than or equal to 40 kg/m2

Exclusion Criteria:

• Current smoking or smoking within the last 6 months
• Current acute or chronic pulmonary disease (except for asthma)
• Proliferative retinopathy requiring acute treatment
• Clinically significant disease history including kidney or liver disease
• Heart disease which limits physical activity or results in discomfort with physical activity
• Pregnancy